Decision Resources and HealthLeaders-InterStudy have produced a new report that finds that the large size of the dyslipidemia prevalent population in the Boston, Chicago and New York City markets makes these metropolitan statistical areas (MSAs) attractive additional targets for overall drug market growth, despite the fact that they already have relatively high treatment rates compared with the top 50 MSAs. According to the new SAMM report entitled Dyslipidemia Drugs: Prospects for Growth in the Top 50 U.S. Markets, the best near-term targets for overall market growth are Los Angeles and Riverside, California. Both MSAs have very low treatment rates, combined with large numbers of prevalent dyslipidemia patients with prescription drug coverage.

The report also finds that AstraZeneca's Crestor and Schering-Plough's Vytorin are battling to claim second place in the $19 billion U.S. dyslipidemia drug market. Maintaining tier 2 formulary status would be lucrative for the two companies.

"BlueCross of California and Kaiser are the dominant managed care players in Northern California. Both are very restrictive and limit access to both Vytorin and Crestor," said Paul Santoro, analyst at Decision Resources. "As part of Schering-Plough's managed care strategy, the company went to the third and fourth largest managed care organizations in this area, BlueShield and Health Net. They were able to secure favorable formulary status of Vytorin with these plans and outperform their drug's national average which has helped them secure second place in the dyslipidemia drug market."

By utilizing a SAMM report, pharmaceutical organizations can help identify the health plans that will have the greatest impact on improving a drug's market share.

"Using this data we would expect other pharmaceutical companies would want to follow Schering-Plough's lead and secure favorable formulary status of their drugs with these two managed care organizations. For example, BlueShield of California and Health Net would help Crestor drive performance in 12 key California markets where the drug performs below its average," continued Mr. Santoro.

About SAMM: Strategic Assessment of Managed Markets

SAMM is a new portfolio from Decision Resources and HealthLeaders- InterStudy that helps pharmaceutical companies target growth potential in health plans and MSAs for their branded drugs. The first SAMM offering is a report series that reveals the information needed to build a bottom-up, city- by-city managed care strategy for individual drug brands. By providing key data on the top 50 metropolitan statistical areas (MSAs) and the top five health plans within those markets, SAMM offers an in-depth look at the prevalence to drug treated ratios for each MSA, the percent of those untreated who are insured/uninsured, formulary access with the top health plans in the market and how brands are performing compared to the national average. It is the first and only market research product to offer drug treatment rates by city.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy is the authoritative source for managed care data, analysis, and news. For more information, please visit http://www.healthleaders-interstudy.com/ .

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall, Decision Resources, Inc. +1-781-296-2563,
emarshall@dresources.com

With Only One Approval in More Than a Decade, the Acute Ischemic Stroke Market is Considered a "Graveyard" for Drug Development

View Now